Blueprint Medicines (BPMC) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

BPMC Blueprint Medicines

Watchlist

89.080
+0.430+0.49%

Trading Oct 15 11:29 ET

5.64BMarket Cap-26123P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Morgan Stanley Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $120
Moomoo NewsOct 11 08:31 ET · Ratings
S&P 500 Futures Decline In Premarket Trading; GXO Logistics, Celsius Holdings Lead
Dow JonesOct 10 07:30 ET
Barclays Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $105
Moomoo NewsOct 10 03:32 ET · Ratings
Blueprint Medicines Insider Sold Shares Worth $324,500, According to a Recent SEC Filing
MT NewswiresOct 4 17:13 ET
Investing in Blueprint Medicines (NASDAQ:BPMC) a Year Ago Would Have Delivered You a 74% Gain
Simply Wall StSep 27 13:01 ET
Stifel Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $155
Moomoo NewsSep 19 20:32 ET · Ratings

Comments

Stock_Drift

Apr 11 20:13

Extended Hours Top Moovers.

$Gryphon Digital Mining (GRYP.US)$ $Zimmer Biomet Holdings (ZBH.US)$ $Cohu Inc (COHU.US)$ $Evolv Technologies (EVLV.US)$ $Brookfield (BN.US)$ $VACASA INC (VCSA.US)$ $Blueprint Medicines (BPMC.US)$ $Williams-Sonoma (WSM.US)$ $U.S. Century Bank (USCB.US)$
📊⚡️📊

frankinglily

Apr 1 03:50

Updated Complete & Utter M&A Guesses Purely for Entertainment Purposes:

$SPDR S&P Biotech ETF (XBI.US)$
$Merck & Co (MRK.US)$ x $Immunovant (IMVT.US)$
$Eli Lilly and Co (LLY.US)$ x $Cytokinetics (CYTK.US)$ (and soon)
$Regeneron Pharmaceuticals (REGN.US)$ x $Apellis Pharmaceuticals (APLS.US)$ (panache & brash)
$Gilead Sciences (GILD.US)$ x % $Madrigal Pharmaceuticals (MDGL.US)$ (liver king)
$Bristol-Myers Squibb (BMY.US)$ x $Iovance Biotherapeutics (IOVA.US)$ (cell Tx boost needed)
$Eli Lilly and Co (LLY.US)$ x $Merus (MRUS.US)$ (partner n...

Moomoo AI

Mar 15 06:44

Insiders selling shares without any recorded purchases over the last year raises caution. The alignment between management and smaller shareholders due to insider ownership is not outstanding. Caution is advised before buying shares in Blueprint Medicines due to significant selling activity.

Possible Bearish Signals With Blueprint Medicines Insiders Disposing Stock

Moomoo AI

Feb 19 12:10

The stock's commendable performance is tied to revenue growth. However, profitability and cash flow checks are crucial for future views. Given the strong share price momentum, the stock warrants a closer look.

Blueprint Medicines (NASDAQ:BPMC) Delivers Shareholders Decent 95% Return Over 1 Year, Surging 16% in the Last Week Alone

Moomoo AI

Jan 29 09:59

Blueprint Medicines' high P/S ratio is worrisome due to its lower projected growth compared to the broader industry. If future revenues don't support this optimism, the current high P/S ratio may not be sustainable. Prices may not be reasonable unless conditions significantly improve.